Retrotope: Individual Patient Expanded Access Protocol for the Treatment of a Single Patient with Progressive Supranuclear Palsy with RT001
The Parkinson’s Institute is the only site worldwide with an FDA-approved compassionate use indication for RT001 in patients with Progressive Supranuclear Palsy (PSP). Learn more about RT001 here.
Status: Active, Not Enrolling
Learn more at retrotope.com. If you are interested, please call (650) 770-0205 or email trials@thepi.org.